Skip to Content

U.S. COVID-19 Vaccine Trial Enrolls 30,000

THURSDAY, Oct. 22, 2020 -- The first company to start a phase 3 trial of a COVID-19 vaccine reached its target of enrolling 30,000 participants, CNN reported Thursday.

The company, Moderna, said that all 30,000 have received the first shot, and most have received the second. Half of the participants were given the vaccine and half received a placebo. Stephen Hoge, M.D., president of Moderna, told CNN that the company is on track to apply to the U.S. Food and Drug Administration for approval to market the vaccine in early December "if all the stars align."

Moderna is one of four phase 3 trials of vaccines, each involving tens of thousands of people, CNN said. The Moderna trial and a trial of the Pfizer vaccine started in July. AstraZeneca began its U.S. trial in August.

Three things need to happen before Moderna applies to the FDA, Hoge told CNN. Of the 30,000 participants, 53 need to become sick with COVID-19. Second is that of the 53 participants who become ill with COVID-19, at least 40 need to have received the placebo. That would show the vaccine is 75 percent effective. Third, the FDA requires that enough time has passed to see if any side effects develop.

CNN Article

© 2020 HealthDay. All rights reserved.

Posted: October 2020

Read this next

Physician's Briefing Weekly Coronavirus Roundup

Here is what the editors at Physician's Briefing chose as the most important COVID-19 developments for you and your practice for the week of Nov. 23 to 25, 2020. This roundup...

U.S. COVID-19 Vaccine Distribution Could Begin in Mid-December

WEDNESDAY, Nov. 25, 2020 -- The Pfizer COVID-19 vaccine could start being distributed in the United States "soon after" a U.S. Food and Drug Administration advisory committee...

Fauci Calls for Americans to Pull Together, Says 'Help Is on the Way'

WEDNESDAY, Nov. 25, 2020 -- During a Thanksgiving week marred by the coronavirus pandemic, Anthony Fauci, M.D., spoke with HD Live! about the need for uniformity in response to...